All News
Best of 2023: Cost-Effective Use of Biological and Targeted Synthetic DMARDs
An international task force of 13 European experts have developed evidence-based points to consider regarding the cost-effective use of biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in the treatment of inflammatory rheumatic diseases (including rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis).
Read Article
Best of 2023: New Laboratory Insights for the ANA+ Consult
A new study suggests that use of ELISA assays for CXCL-10 and IFN-α can predict which ANA+ individuals may progress to developing a systemic autoimmune rheumatic disease (SARD).
Read Article
Best of 2023: How Being a Patient Taught Me to Be a Better Doctor
Since I can remember, I always wanted to be a doctor. My dad was a trauma surgeon and my mom a nurse.
https://t.co/JE4QoJy4jp https://t.co/jrJoqRD30P
Dr. John Cush RheumNow ( View Tweet)
Best of 2023: LAVLI - A New Autoinflammatory Disorder
NIH researchers have have described a novel autoinflammatory disorder called "Lyn kinase-associated vasculopathy and liver fibrosis" (LAVLI), based on a mutation in the LYN gene.
https://t.co/5nzq6KvOpy https://t.co/Y2MCXkGck2
Dr. John Cush RheumNow ( View Tweet)
STOP-RA study on HCQ preventing RA... HCQ did NOT prevent RA development in pre-RA pts
#RNL2023 https://t.co/BqZlajMOLK https://t.co/Omui3LWiPi
Links:
Dr. John Cush RheumNow ( View Tweet)
Avacopan in GPA
- non-inferior to prednisone for induction remission
- received FDA approval for treatment of severe active GPA in combo with standard therapy and steroids
- should be used in newly diagnosed active or relapsing disease
@rheumnow
#RNL2023 https://t.co/yxujTvbVGp https://t.co/UfOkrJDgcU
Links:
Dr. John Cush RheumNow ( View Tweet)
Full Read comprehensive review by Isenberg et al-what Rx works in SLE; review of RCT data on approved & developing drugs:
- Obinutuzumab
- Dapirolizumab
- Deucravacitinib
- Litifilimab
- Atacicept
- Telitacicept
https://t.co/4JvbZ6ysWn https://t.co/FePnuTsHhN
Dr. John Cush RheumNow ( View Tweet)
Does King Charles have Sausage Digits (dactylitis) or OA? https://t.co/HpOdaXAxff https://t.co/HpOdaXAxff https://t.co/IrjJcxUG9b
Links:
Dr. John Cush RheumNow ( View Tweet)
MSK Syndrome from Dupilimab, an IL-4/13 Inhibitor. A new MSK syndrome of inflammatory enthesitis/arthritis/tenosynovitis has been described in atopic dermatitis (AD) patients treated with the IL-4 receptor antagonist, dupilumab. https://t.co/w5djtUzAGG https://t.co/eGMJQJ6Pw2
Dr. John Cush RheumNow ( View Tweet)
Prospective study.of 370 #FM pts (79% F; age 34yrs), and 79% were female w/ 14.3 tender points. A delay in Dx was signif correlated with Sx Severity Scale (r = 0.14) & tender points (r = 0.16), but not widespread pain. Early Dx = less severe FM. https://t.co/URvzRa1c3P
Dr. John Cush RheumNow ( View Tweet)
Analysis of 14,958 RA pts in Japans National Database of Rheumatic Diseases (NinJa) shows women had higher DAS28-ESR values than males, despite no obvious difference in other indices or disease activity categories. https://t.co/bLFmRdulCw
Dr. John Cush RheumNow ( View Tweet)
Metanalysis of Steroids in hosp community-acquired pneumonia (CAP). 18 studies, 4661 pts. Corticosteroids reduced mortality in more severe CAP(RR 0.62; 0.45 to 0.85), but not less severe CAP(RR 1.08). Steroids lower need for mech ventilation, ICU https://t.co/1QbuCZRXze https://t.co/16qiqIatJq
Dr. John Cush RheumNow ( View Tweet)
A Danish national registry study compared RA pts taking JAKi (n 875) and bDMARDs (n 4247). They found similar rates of subsequent cancers (14.4 vs 12.9/ per 1000 PYRS); with a nonsignificant risk (HR1.41; CI 0.76, 2.37) https://t.co/LNIqQxQFKK
Links:
Dr. John Cush RheumNow ( View Tweet)
Denosumab Reduces Type II Diabetes Risk. The British Medical Journal has published a matched cohort analysis demonstrating that adults receiving denosumab had a lower risk of NIDDM compared with those taking oral bisphosphonates for osteoporosis. https://t.co/vZALPMU8lI https://t.co/yGvDLHIp5y
Dr. John Cush RheumNow ( View Tweet)
RheumNow Live is just about a month away--will we see you there?
You can attend virtually or in-person at our Dallas, TX location. With over 20 dynamic speakers, we are confident you'll leave feeling inspired!
https://t.co/y6BVvZDcku https://t.co/NqzkVd3l8p
Links:
Dr. John Cush RheumNow ( View Tweet)
How Being a Patient Taught Me to Be a Better Doctor” Dr. Marcella Ferrada (@maferradastrong ) shares her experience having a rare disease and how it positively impacted her skills as a physician. https://t.co/BZPlLzdSsk https://t.co/Ykh6AhAnxn
Dr. John Cush RheumNow ( View Tweet)
Browse through this update to learn more about the real impact of comorbidities on patients living with SpA. Sponsored by Novartis Medical Affairs.
https://t.co/0BCVvTYzAl https://t.co/2RhJomr6Dr
Dr. John Cush RheumNow ( View Tweet)
Denosumab Reduces Type II Diabetes Risk. The British Medical Journal has published a matched cohort analysis demonstrating that adults receiving denosumab had a lower risk of NIDDM compared with those taking oral bisphosphonates for osteoporosis. https://t.co/eUu23a2QDn https://t.co/RHDLTm9NMD
Dr. John Cush RheumNow ( View Tweet)
RHEUMATOLOGIST SURVEY QUESTION - Is TYK2 part of the Janus Kinase family?
Click here to answer >> https://t.co/IagcDC24rZ
Dr. John Cush RheumNow ( View Tweet)
Bimekizumab in Hidradenitis Supprativa (HS) - results of 2 phase III BE HEARD I & II trials show Week 16 50% HS Responses to be 48% and 52% (vs PBO 29% and 32%). >75% maintained response out to wk 48; at wk 48, a 75% HS response seen in 55%. https://t.co/vAMPWV1gKi
Dr. John Cush RheumNow ( View Tweet)